NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04394975,Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer,https://clinicaltrials.gov/study/NCT04394975,,ACTIVE_NOT_RECRUITING,"This is a randomized, open-label, controlled, multicenter, phase III trial to compare the efficacy and safety of Toripalimab in combination with axitinib to sunitinib monotherapy as a first-line therapy for advanced RCC. Eligible patients will be randomized 1:1 to receive the combination therapy of Toripalimab and axitinib or sunitinib monotherapy.",NO,Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1,COMBINATION_PRODUCT: Biological : Toripalimab Drug: Axitinib|DRUG: sunitinib,"PFS assessed by IRC per RECIST 1.1., To compare the progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST) 1.1 as assessed by independent review committee (IRC) in subjects treated with Toripalimab plus axitinib vesus sunitinib monotherapy as a first-line treatment for advanced RCC., 3 years","PFS assessed by investigators per RECIST 1.1;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using RECIST 1.1 to determine tumor response;, 3 years|ORR assessed by investigators and IRC per RECIST 1.1, respectively;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;, 3 years|DOR, assessed by investigators and IRC per RECIST 1.1, respectively;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;, 3 years|DCR assessed by investigators and IRC per RECIST 1.1, respectively;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;, 3 years|overall survival rate assessed by investigators and IRC per RECIST 1.1, respectively;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;, 3 years|OS assessed by investigators and IRC per RECIST 1.1, respectively;, The treatment effect of with Toripalimab plus axitinib vesus sunitinib monotherapy, will be assessed using IRC and RECIST 1.1 to determine tumor response;, 3 years|Incidence and grade of AEs and SAEs per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, incidence of ≥ grade 3 AE;, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 3 years|Incidence and grade of AEs and SAEs related to study drugs per NCI-CTCAE version 5.0, AEs ≥ grade 3 related to the study drugs., Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 3 years","Biomarker, Correlation between biomarker (PD-L1) and the efficacy of Toripalimab, 2 years","Shanghai Junshi Bioscience Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,421,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,JS001-036-Ⅲ-RCC,2020-08-20,2025-02-28,2025-02-28,2020-05-20,,2025-03-25,"Beijing Cancer Hospital, Beijing, China",
